DOSE-RELATED IMMUNOLOGICAL EFFECTS OF LEVAMISOLE IN PATIENTS WITH CANCER

被引:35
作者
JANIK, J
KOPP, WC
SMITH, JW
LONGO, DL
ALVORD, WG
SHARFMAN, WH
FENTON, RG
SZNOL, M
STEIS, RG
CREEKMORE, SP
EWEL, CH
HURSEY, J
URBA, WJ
机构
[1] NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAM,POB B,FREDERICK,MD 21702
[2] NCI,FREDERICK CANC RES & DEV CTR,DATA MANAGEMENT SERV INC,FREDERICK,MD 21701
[3] NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,FREDERICK,MD 21701
[4] FREDERICK MEM HOSP,FREDERICK,MD
[5] NCI,DIV CANC TREATMENT,CANC THERAPY EVALUAT PROGRAM,INVEST DRUG BRANCH,BETHESDA,MD 20892
关键词
D O I
10.1200/JCO.1993.11.1.125
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This phase I study was conducted to determine the maximum- tolerated dose (MTD) and the immunologic properties of levamisole in cancer patients when administered alone and in combination with interferon gamma (IFN-γ). Patients and Methods: Twenty patients with advanced cancer and 36 patients with completely resected melanoma (n = 33) or renal cell cancer (n = 3) received levamisole orally every other day for six doses at 1.0, 2.5, 5.0, or 10.0 mg/kg. Ten days later, patients restarted levamisole and began IFN- γ 0.1 mg/m2 by subcutaneous injection every other day. Blood samples were collected for measurement of neopterin and soluble interleukin-2 receptor (sIL-2R), and for flow-cytometric analysis. Results: The MTD of levamisole was 5 mg/kg, and this was not changed by the addition of IFN-γ. Dose- related increases in serum levels of neopterin and sIL-2R were noted. Multiple doses of ≥ 5 mg/kg of levamisole were required to elicit immune changes, which were more prominent in patients with minimal tumor burdens. Increased expression of CD64 and class I and class II major histocompatibility antigens on monocytes was also observed. The combination of IFN-γ and levamisole did not result in greater immunologic effects than those observed in previous trials of IFN-γ alone. Conclusion: Levamisole induces dose-related immunologic changes in patients with large or minimal tumor burdens. These changes may be involved in the beneficial effects noted in recent adjuvant trials of levamisole. Ongoing clinical trials should correlate immune changes with response, and trials exploring different schedules of administration using higher, more immunologically active, doses of levamisole should be performed.
引用
收藏
页码:125 / 135
页数:11
相关论文
共 42 条
[1]  
FISCHER GW, 1978, CANCER TREAT REP, V62, P1637
[2]   HUMAN BIOLOGIC RESPONSE MODIFICATION BY INTERFERON IN THE ABSENCE OF MEASURABLE SERUM CONCENTRATIONS - A COMPARATIVE TRIAL OF SUBCUTANEOUS AND INTRAVENOUS INTERFERON-BETA SERINE [J].
GOLDSTEIN, D ;
SIELAFF, KM ;
STORER, BE ;
BROWN, RR ;
DATTA, SP ;
WITT, PL ;
TEITELBAUM, AP ;
SMALLEY, RV ;
BORDEN, EC .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (14) :1061-1068
[3]   TOXICITY OF LEVAMISOLE AND 5-FLUOROURACIL IN HUMAN-COLON CARCINOMA-CELLS [J].
GREM, JL ;
ALLEGRA, CJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (18) :1413-1417
[4]  
GROVEMAN DS, 1983, J BIOL RESP MODIF, V2, P167
[5]   EFFECTS OF LEVAMISOLE AND IMIDAZOLE ON LYMPHOCYTE-PROLIFERATION AND CYCLIC NUCLEOTIDE LEVELS [J].
HADDEN, JW ;
COFFEY, RG ;
HADDEN, EM ;
LOPEZCORRALES, E ;
SUNSHINE, GH .
CELLULAR IMMUNOLOGY, 1975, 20 (01) :98-103
[6]   MONOCYTE-MEDIATED SUPPRESSION OF LYMPHOCYTE-T PROLIFERATIVE RESPONSE IN BREAST AND COLORECTAL-CANCER PATIENTS - SPECIFIC ACTION OF LEVAMISOLE ON SUPPRESSOR MONOCYTES [J].
HAN, T ;
NEMOTO, T ;
LEDESMA, EJ ;
BRUNO, S ;
AMERY, WK .
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1981, 3 (01) :103-111
[7]  
HOEBEKE J, 1973, J RETICULOENDOTH SOC, V14, P317
[8]   IMMUNE-RESPONSE ASSOCIATED PRODUCTION OF NEOPTERIN - RELEASE FROM MACROPHAGES PRIMARILY UNDER CONTROL OF INTERFERON-GAMMA [J].
HUBER, C ;
BATCHELOR, JR ;
FUCHS, D ;
HAUSEN, A ;
LANG, A ;
NIEDERWIESER, D ;
REIBNEGGER, G ;
SWETLY, P ;
TROPPMAIR, J ;
WACHTER, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1984, 160 (01) :310-316
[9]  
HUBER C, 1983, J IMMUNOL, V130, P1047
[10]  
KAZURA JW, 1979, CLIN EXP IMMUNOL, V35, P258